Select Language
CD47
CD47 Overview
| English Name | Cluster of differentiation 47 | Approved Drugs | 0 |
| Drugs in Clinical Trials | 48 | Target Synonym | MER6，CD47，Leukocyte surface antigen CD47，CD47 Molecule，Antigenic Surface Determinant Protein OA3，CD47 Antigen (Rh-Related Antigen， Integrin-Associated Signal Transducer)，Antigen Identified By Monoclonal Antibody 1D8，Integrin Associated Protein，Rh-Related Antigen，CD47 Glycoprotein，IAP，Integrin-Associated Signal Transducer，Protein MER6，OA3，CD47 Antigen，Integrin-Associated Protein |
| Highest Development Stage | Phase 3 Clinical | ||
| English Name | Cluster of differentiation 47 |
| Target Synonym | MER6，CD47，Leukocyte surface antigen CD47，CD47 Molecule，Antigenic Surface Determinant Protein OA3，CD47 Antigen (Rh-Related Antigen， Integrin-Associated Signal Transducer)，Antigen Identified By Monoclonal Antibody 1D8，Integrin Associated Protein，Rh-Related Antigen，CD47 Glycoprotein，IAP，Integrin-Associated Signal Transducer，Protein MER6，OA3，CD47 Antigen，Integrin-Associated Protein |
| Approved Drugs | 0 |
| Drugs in Clinical Trials | 48 |
| Highest Development Stage | Phase 3 Clinical |
CD47 Product List
- Product Category
Protein (21)Beads (1)Kits (2)
- Product Status
Launched (24)
- Species
Human (12)Mouse (5)Cynomolgus / Rhesus macaque (4)Rat (1)Rabbit (1)Canine (1)
- Tag
Fc Tag (5)His Tag (6)Fc Tag & Avi Tag (3)Mouse IgG Fc Tag (2)His Tag & Avi Tag (4)Mouse IgG Fc Tag & Avi Tag (1)- (3)
- Conjugate
Unconjugated (13)Biotin-labeled (7)FITC Labeled (1)- (3)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|---|
HOT CD7-H5227 |  Human | HEK293 | Human CD47 Protein, His Tag (MALS verified) |  |  |  |
HOT CD7-H522a | Human | HEK293 | Human CD47 Protein, His Tag, low endotoxin (MALS verified) |  | | |
HOT CD7-H82E9 | Human | HEK293 | Biotinylated Human CD47 Protein, His,Avitag™ (MALS verified) |  | | |
HOT CD7-M5251 |  Mouse | HEK293 | Mouse CD47 Protein, Fc Tag (MALS verified) |  | | |
HOT CD7-C52H1 |  Cynomolgus / Rhesus macaque | HEK293 | Cynomolgus / Rhesus macaque CD47 Protein, His Tag, low endotoxin |  | | |
CD7-H5256 | Human | HEK293 | Human CD47 Protein, Fc Tag, low endotoxin (MALS verified) |  | | |
CD7-H52A5 | Human | HEK293 | Human CD47 Protein, Mouse IgG2a Fc Tag, low endotoxin |  | | |
CD7-H82A3 | Human | HEK293 | Biotinylated Human CD47 Protein, Mouse IgG2a Fc,Avitag™ (MALS verified) |  | | |
CD7-H82F6 | Human | HEK293 | Biotinylated Human CD47 Protein, Fc,Avitag™ (MALS verified) |  | | |
CD7-HA2E9 | Human | HEK293 | Unconjugated Human CD47 Protein, His,Avitag™ (HPLC verified) |  | | |
Total: 24
- 1
- 2
- 3
CD47 Background
Leukocyte surface antigen CD47 is also known as Antigenic surface determinant protein OA3, Integrin-associated protein (IAP) and Protein MER6. CD47 contains 1 Ig-like V-type (immunoglobulin-like) domain. CD47 is very broadly distributed on normal adult tissues. CD47 has a role in both cell adhesion by acting as an adhesion receptor for THBS1 on platelets, and in the modulation of integrins and plays an important role in memory formation and synaptic plasticity in the hippocampus by similarity. CD47 is the receptor for SIRPA, binding to which prevents maturation of immature dendritic cells and inhibits cytokine production by mature dendritic cells. CD47 Interaction with SIRPG mediates cell-cell adhesion, enhances superantigen-dependent T-cell-mediated proliferation and costimulates T-cell activation.
CD47 Synonyms
CD47,MER6,IAP,OA3
Project Cooperation
| Project Name | Drug Type | Therapeutic Area | Indication | Stage | Rights Area |
|---|---|---|---|---|---|
| CD47 Monoclonal Antibody | Monospecific antibody | Oncology/Cancer | Advanced solid tumor,Advanced hematological tumor | IND | Global |
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| IMC-002(Immuneoncia) | IMC-002; 3D-197; 3D197 | Phase 3 Clinical | Immuneoncia Therapeutics Inc | Hematologic Neoplasms; Lymphoma; Neoplasm Metastasis; Neoplasms; Neuromyelitis Optica; Solid tumours; Stomach Neoplasms | Details |
| Timdarpacept | IMM01; IMM 01; IMC-001 | Phase 3 Clinical | Atherosclerosis; Cardiovascular Diseases; Hematologic Neoplasms; Hodgkin Disease; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Leukemia, Promyelocytic, Acute; Lymphoma; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Non-Hodgkin; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms; Solid tumours | Details | |
| Evorpacept | ALX148; ALX-148 | Phase 3 Clinical | Alexo Therapeutics | Carcinoma, Transitional Cell; Composite Lymphoma; Esophageal Neoplasms; Head and Neck Neoplasms; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Metastatic breast cancer; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasm Metastasis; Neoplasms; Oropharyngeal Neoplasms; Plasmablastic Lymphoma; Primary mediastinal B cell lymphoma; Richter's Syndrome; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Urinary Bladder Neoplasms | Details |
| Amulirafusp alfa | IMC-002; IMM-0306 | Phase 3 Clinical | Glomerulonephritis, Membranous; Lupus Erythematosus, Systemic; Lupus Nephritis; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Nephrosis; Neuromyelitis Optica | Details | |
| Ligufalimab | AK-117 | Phase 3 Clinical | Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Esophageal Neoplasms; Hodgkin Disease; Leukemia, Myeloid, Acute; Lymphoma; Myelodysplastic Syndromes; Neoplasms; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms | Details | |
| Magrolimab | 5F9; Hu5F9-G4; ONO-7913; GS-4721 | Phase 2 Clinical | Stanford University | Brain Neoplasms; Carcinoma, Transitional Cell; Colorectal Neoplasms; Hodgkin Disease; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Multiple Myeloma; Mycosis Fungoides; Myelodysplastic Syndromes; Neuroblastoma; Osteosarcoma; Ovarian Neoplasms; Pancreatic Neoplasms; Sezary Syndrome; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms | Details |
| AO-176 | AO-176; Ti-104; Ti-108; Ti-176 | Phase 2 Clinical | Arch Oncology Inc | Multiple Myeloma; Solid tumours | Details |
| Ontorpacept | TTI-621 | Phase 2 Clinical | The Hospital For Sick Children, Trillium Therapeutics Inc, University Health Network (Uhn) | Breast Neoplasms; Carcinoma, Merkel Cell; Carcinoma, Squamous Cell; Hematologic Neoplasms; Leiomyosarcoma; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Melanoma; Multiple Myeloma; Mycosis Fungoides; Papillomavirus Infections; Primary mediastinal B cell lymphoma; Sarcoma; Skin Neoplasms; Solid tumours | Details |
| AUR-103 | AUR-103 | Phase 2 Clinical | Aurigene | Gastroesophageal Junction Neoplasms; Leukemia; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Myelodysplastic Syndromes; Solid tumours; Stomach Neoplasms | Details |
| Maplirpacept | TTI-622; PF-07901801 | Phase 2 Clinical | Trillium Therapeutics Inc | Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Hematologic Neoplasms; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Multiple Myeloma; Ovarian Neoplasms; Peritoneal Neoplasms; Primary mediastinal B cell lymphoma; Skin Neoplasms | Details |
| DSP-107 | KAHR-107; DSP-107 | Phase 2 Clinical | Kahr Medical | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Solid tumours | Details |
| BRB-002 | BRB-002 | Phase 2 Clinical | Bitterroot Bio Inc | Atherosclerosis; Cardiovascular Diseases; Vasculitis | Details |
| HCB-101 | HCB-101 | Phase 2 Clinical | HanchorBio Inc | Carcinoma, Renal Cell; Colorectal Neoplasms; Lymphoma, Non-Hodgkin; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms | Details |
| LB-101 (Centessa Pharmaceuticals) | LB-101 (Centessa Pharmaceuticals); LB-101 Tetravalent PD-L1xCD47 LockBody bispecific monoclonal antibody | Phase 2 Clinical | Centessa Pharmaceuticals Plc | Solid tumours | Details |
| Spevatamig | PT-886; PT886 | Phase 2 Clinical | Phanes Therapeutics Inc | Biliary Tract Neoplasms; Carcinoma, Pancreatic Ductal; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| Peluntamig | PT-217 | Phase 2 Clinical | Phanes Therapeutics Inc | Carcinoma, Neuroendocrine; Neuroendocrine Carcinoma of Lung; Prostatic Neoplasms; Small Cell Lung Carcinoma; Solid tumours | Details |
| BCD-106 | BCD-106 | Phase 2 Clinical | BIOCAD JSC | Solid tumours | Details |
| BAT-7104 | BAT-7104 | Phase 2 Clinical | Bio-Thera Solutions Ltd | Neoplasms; Solid tumours | Details |
| IMM-2902 | IMM-2902 | Phase 2 Clinical | Breast Neoplasms; Cholangiocarcinoma; Lung Neoplasms; Solid tumours; Stomach Neoplasms | Details | |
| 6MW-3211 | 6MW3211; 6MW-3211 | Phase 2 Clinical | Mabwell (Shanghai) Bioscience Co Ltd | Carcinoma, Renal Cell; Leukemia, Myeloid, Acute; Lung Neoplasms; Lymphoma; Myelodysplastic Syndromes; Neoplasms | Details |
| JMT-601 | JMT-601 | Phase 2 Clinical | Shanghai Jmt-Bio Inc | Glomerulonephritis, Membranous; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Nephrosis | Details |
| Lemzoparlimab | ABBV-IMAB-TJC4; TJ-1133; TJ-011133; TJC-4 | Phase 2 Clinical | Abbvie Inc, I-Mab Biopharma Co Ltd | Hematologic Neoplasms; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Solid tumours | Details |
| Anti-CD47 monoclonal antibody (Biocad) | Phase 1 Clinical | BIOCAD JSC | Neoplasms | Details | |
| Recombinant humanized monoclonal antibody MIL95 (Mabworks/Connaught Biomedical Technology) | MIL-95; CM-312 | Phase 1 Clinical | Beijing Mabworks Biotech Co Ltd | Leukemia, Myeloid, Acute; Lymphoma; Neoplasms; Solid tumours | Details |
| Zeripatamig | TG-1801; NI-1701 | Phase 1 Clinical | Novimmune Sa | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Richter's Syndrome | Details |
| SL-172154 | SL-172154; SIRPα -Fc-CD40L | Phase 1 Clinical | Shattuck Labs Inc | Carcinoma, Ovarian Epithelial; Carcinoma, Squamous Cell; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Ovarian Neoplasms; Peritoneal Neoplasms; Squamous Cell Carcinoma of Head and Neck | Details |
| Simridarlimab | IBI-322; IBI322 | Phase 1 Clinical | Bone Marrow Neoplasms; Hematologic Neoplasms; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, T-Cell; Neoplasms; Solid tumours | Details | |
| anti-CD47 mAb (Hangzhou Sumgen Biotechnology/Zhongsheng Sumgen Biotechnology) | SG-404 (Hangzhou Sumgen) | Phase 1 Clinical | Zhongsheng Shangjian Biological Medicine (Hangzhou) Co Ltd | Hematologic Neoplasms; Solid tumours | Details |
| anti-CD47/CD20 bispecific antibody (Bristol-Myers Squibb Co) | Phase 1 Clinical | Bristol-Myers Squibb Company | Hematologic Neoplasms; Lymphoma, Non-Hodgkin | Details | |
| ZL-1201 | ZL-1201 | Phase 1 Clinical | Zai Lab (Shanghai) Co Ltd | Hematologic Neoplasms; Neoplasms; Solid tumours | Details |
| HMPL-A83 | HMPL-A-83; HMPL-A83 | Phase 1 Clinical | Hematologic Neoplasms; Neoplasms; Solid tumours | Details | |
| NI-1801 | NI-1801 | Phase 1 Clinical | Light Chain Bioscience Ltd | Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Pancreatic Ductal; Solid tumours; Triple Negative Breast Neoplasms | Details |
| IMM-0306S | IMM0306S; IMM-0306S | Phase 1 Clinical | Lupus Erythematosus, Systemic | Details | |
| AK-132 | AK132; AK-132 | Phase 1 Clinical | Neoplasms; Solid tumours | Details | |
| D3L-001 | D3L-001 | Phase 1 Clinical | D3 Bio (Wuxi) Co Ltd | Neoplasms; Solid tumours | Details |
| FP-002 (Fapon Biopharma) | FP-002 | Phase 1 Clinical | Guangdong Fapon Biopharma Inc | Neoplasms; Solid tumours | Details |
| BC-007 (Dragonboat Biopharmaceutical) | BC-007 | Phase 1 Clinical | Dragonboat Biopharmaceutical | Neoplasms; Solid tumours | Details |
| SG-1906 | SG-1906; SG1906 | Phase 1 Clinical | Hangzhou Shangjian Biotechnology Co Ltd | Neoplasms; Solid tumours | Details |
| LD-002 | LD-002 | Phase 1 Clinical | Zhejiang Blue Shield Pharmaceutical Co Ltd | Hematologic Neoplasms; Lymphoma, Non-Hodgkin; Solid tumours | Details |
| SHS-009 | SHS-009; SH009; SH-009 | Phase 1 Clinical | Nanjing Sanhome Pharmaceutical Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Liver Neoplasms; Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms | Details |
| Monoclonal Antibody (Mab) sB24M | Phase 1 Clinical | Swiss Biopharma Med GmbH | Pyoderma; Pyoderma Gangrenosum | Details | |
| IMM-2520 | IMM-2520 | Phase 1 Clinical | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details | |
| STI-6643 | STI-6643 | Phase 1 Clinical | Sorrento Therapeutics Inc | Neoplasms; Solid tumours | Details |
| PF-07257876 | Phase 1 Clinical | Pfizer Inc | Carcinoma, Non-Small-Cell Lung; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck | Details | |
| TQB-2928 | TQB-2928 | Phase 1 Clinical | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung; Hematologic Neoplasms; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasms; Osteosarcoma; Solid tumours | Details |
| IMM2505 | IMM2505; IMM-2505 | Phase 1 Clinical | SunHo (China) BioPharmaceutical Co Ltd | Solid tumours | Details |
| SG404 | SG-404; SG404 | Phase 1 Clinical | Hangzhou Shangjian Biotechnology Co Ltd | Neoplasms | Details |
| Kintuzumab(GenSci) | Phase 1 Clinical | Changchun GeneScience Pharmaceuticals Co Ltd | Hematologic Neoplasms; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, Non-Hodgkin; Myelodysplastic Syndromes; Solid tumours | Details |
Product Reviews
L***z2026-02-12
0People LikeI have been using the protein for ELISA assays, andit has met our experimental requirements without any issues. Low doses are sufficient for coating, which makes the assays cost-effective while still providing strong and consistent signal. The shipping was fast and the product arrived in excellent condition.- A***r2023-01-31 0People LikeA new ELISA binding was set up with this new recombinant protein. Among the various suppliers evaluated, the one from Acro Biosystem has been selected. Low doses are needed for coating in comparison to other providers. In addition, data quality was confirmed on repeatition runs. Finally, product delivery was quick and the interaction with our local business development manager is highly satisfaying.
- R***e2022-09-10 0People LikeHeard about ACRO from word of mouth from coworkers here at PPD and decided to browse the internet . My team purchased this product for some ELISA testing at the lab. We have been satisfied with the results so far. Great repeatability, sustainability, and specificity as compared to other vendors! It’s very creditable in my opinion. All and all ACRO definitely has some great quality products that are also more cost-effective compared to different vendors like MSD!
Load More
- Overview
- Product List
- Product Reviews
- Clinical Drug Information
Share to: